DTI for Injection

DTI for Injection Dosage/Direction for Use



Korea United Pharm [KR]


Full Prescribing Info
Dosage/Direction for Use
Hodgkin's Disease: The recommended dosage of dacarbazine in the treatment of Hodgkin's disease is 150 mg/square meter body surface/day for 5 days, in combination with other effective drugs. Treatment may be repeated every 4 weeks. An alternative recommended dosage is 375 mg/square meter body surface on day 1, in combination with other effective drugs, to be repeated every 15 days.
Malignant Melanoma: The recommended dosage is 2 to 4.5 mg/kg/day for 10 days. Treatment may be repeated at 4 week intervals. An alternate recommended dosage is 250 mg/square meter body surface/day I.V. for 5 days. Treatment may be repeated every 3 weeks.
Maximum dose: Dose up to 200 mg/m2 may be given as a slow intravenous injection. Larger doses (ranging from 200 to 850 mg/m2) should be administered as an i.v. infusion over 15 - 30 minutes.
Mode of Administration: Preparation for administration: Hazardous agent; use appropriate precautions for handling and disposal.
Reconstitution: Dacarbazine 100 mg and 200 mg/vial are reconstituted with 9.9 ml and 19.7 ml, of Sterile Water for Injection respectively, the resulting solution contains 10 mg/ml of dacarbazine having a pH of 3.0 - 4.0. Reconstituted solution may be administered by IV push over a 1-minute period. Alternatively, the reconstituted solution may be further diluted with 5% dextrose injection, or 0.9% sodium chloride injection, and infused IV over a 15- to 30-minute period.
After reconstitution and prior to use, the solution in the vial may be stored under refrigeration (4°C) for up to 72 hours or at normal room temperature (20°C) for up to 8 hours when protect from light. Solutions diluted for infusion (in D5W or NS) are stable for 24 hours refrigerated and for 8 hours at room temperature if protected from light. Decompose drug turns pink.
Dacarbazine is sensitive to light exposure.
All reconstituted solutions should be suitably protected from light also during administration (light-resistant infusion set).
Dacarbazine is sensitive to light and heat; elevated temperatures may cause a color change from ivory to pink which is indicative of some decomposition.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in